中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2015年
16期
54-56
,共3页
多囊卵巢综合征%内分泌紊乱%胰岛素增敏剂
多囊卵巢綜閤徵%內分泌紊亂%胰島素增敏劑
다낭란소종합정%내분비문란%이도소증민제
Polycystic ovary syndrome%Endocrine disorders%Insulin sensitizing agent
目的:探讨多囊卵巢综合征内分泌紊乱患者胰岛素增敏剂的使用疗效。方法:选择本院2012年8月-2013年11月收治的56例多囊卵巢综合征患者为研究对象,随机数字表法分为对照组28例,观察组28例,对照组行枸橼氯米芬、妈富隆、戊酸雌二醇片联合治疗,观察组在对照组治疗基础上加入胰岛素增敏剂治疗,对两组患者治疗后效果进行分析。结果:观察组治疗总有效率为92.86%,对照组为71.43%,比较差异有统计学意义(P<0.05);观察组患者在各个时间段的胰岛素水平以及胰岛素抵抗指数都明显低于对照组,比较差异有统计学意义(P<0.05)。结论:在常规治疗方案基础上加用胰岛素增敏剂对多囊卵巢综合征内分泌紊乱患者进行治疗,效果显著,安全性高,值得临床进一步推广使用。
目的:探討多囊卵巢綜閤徵內分泌紊亂患者胰島素增敏劑的使用療效。方法:選擇本院2012年8月-2013年11月收治的56例多囊卵巢綜閤徵患者為研究對象,隨機數字錶法分為對照組28例,觀察組28例,對照組行枸櫞氯米芬、媽富隆、戊痠雌二醇片聯閤治療,觀察組在對照組治療基礎上加入胰島素增敏劑治療,對兩組患者治療後效果進行分析。結果:觀察組治療總有效率為92.86%,對照組為71.43%,比較差異有統計學意義(P<0.05);觀察組患者在各箇時間段的胰島素水平以及胰島素牴抗指數都明顯低于對照組,比較差異有統計學意義(P<0.05)。結論:在常規治療方案基礎上加用胰島素增敏劑對多囊卵巢綜閤徵內分泌紊亂患者進行治療,效果顯著,安全性高,值得臨床進一步推廣使用。
목적:탐토다낭란소종합정내분비문란환자이도소증민제적사용료효。방법:선택본원2012년8월-2013년11월수치적56례다낭란소종합정환자위연구대상,수궤수자표법분위대조조28례,관찰조28례,대조조행구연록미분、마부륭、무산자이순편연합치료,관찰조재대조조치료기출상가입이도소증민제치료,대량조환자치료후효과진행분석。결과:관찰조치료총유효솔위92.86%,대조조위71.43%,비교차이유통계학의의(P<0.05);관찰조환자재각개시간단적이도소수평이급이도소저항지수도명현저우대조조,비교차이유통계학의의(P<0.05)。결론:재상규치료방안기출상가용이도소증민제대다낭란소종합정내분비문란환자진행치료,효과현저,안전성고,치득림상진일보추엄사용。
Objective:To investigate the curative effect of polycystic ovary syndrome patients with comprehensive use of insulin sensitizing agent endocrine disorders.Method:In our hospital in 2012 August to 2013 November 56 polycystic ovary syndrome patients were selected as the research objects,and randomly divided into 28 cases in control group and 28 cases in observation group,the control group accpeted citric clomiphene citrate,Marvelon,Xu acid Estradiol Tablets combined treatment,the observation group based on the control group accepted insulin sensitizing sensitive agent treatment,the two groups were analyzed after treatment.Result:In the observation group the total effective rate was 92.86%,71.43% in the control group, the difference was statistically significant (P<0.05).In all the time,insulin levels of the observation group were lower than those of the control group (P<0.05).Conclusion:Based on conventional treatment scheme on the use of insulin sensitizing agent for the treatment of polycystic ovary syndrome,endocrine disorders in patients with significant effect,high safety,is worth to be popularized in clinical use.